Karolina Maciag

Karolina Maciag

Auto-generated profile, based on publicly available information

Karolina Maciag

Division of Allergy and Infectious Diseases, University of Washington , Seattle, WA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2024 in The Journal of Immunology
Verified
Journal Article
Open access
KMKarolina Maciag
Karolina Maciag
CPCourtney R Plumlee
Courtney R Plumlee
SCSara B Cohen
Sara B Cohen
BGBenjamin H Gern
Benjamin H Gern
KUKevin B. Urdahl
Kevin B. Urdahl
T cells producing IFN-γ have long been considered a stalwart for immune protection against Mycobacterium tuberculosis (Mtb), but their relative importance to pulmonary immunity has been challenged by murine studies that achieved protection by adoptively transferred Mtb-specific IFN-γ−/− T cells. Using IFN-γ−/− T cell chimeric mice and adoptive transfer of IFN-γ−/− T cells into TCRβ−/−δ−/− mice, we demonstrate that control of lung Mtb burden is in fact dependent on T cell–derived IFN-γ, and, furthermore, mice selectively deficient in T cell–derived IFN-γ develop exacerbated disease compared with T cell–deficient control animals, despite equivalent lung bacterial burdens. Deficiency in T cell–derived IFN-γ skews infected and bystander monocyte-derived macrophages to an alternative M2 phenotype and promotes neutrophil and eosinophil influx. Our studies support an important role for T cell–derived IFN-γ in pulmonary immunity against tuberculosis.

5 April 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
KMKarolina Maciag
Karolina Maciag
CPCourtney R. Plumlee
Courtney R. Plumlee
SCSara B. Cohen
Sara B. Cohen
BGBenjamin H. Gern
Benjamin H. Gern
KUKevin B. Urdahl
Kevin B. Urdahl
T cells producing interferon gamma (IFNγ) have long been considered a stalwart for immune protection against Mycobacterium tuberculosis ( Mtb ), but their relative importance to pulmonary immunity has been challenged by murine studies which achieved protection by adoptively transferred Mtb -specific IFNγ -/- T cells. Using IFNγ -/- T cell chimeric mice and adoptive transfer of IFNγ -/- T cells into TCRβ -/- δ -/- mice, we demonstrate that control of lung Mtb burden is in fact dependent on T cell-derived IFNγ, and furthermore, mice selectively deficient in T cell-derived IFNγ develop exacerbated disease compared to T cell-deficient controls despite equivalent lung bacterial burdens. Deficiency in T cell-derived IFNγ skews infected and bystander monocyte-derived macrophages (MDMs) to an alternative M2 phenotype, and promotes neutrophil and eosinophil influx. Our studies support an important role for T cell-derived IFNγ in pulmonary immunity against TB.

3 April 2023
Verified
Other
Open access
ZZZehua Zhu
Zehua Zhu
Amir ArefAmir Aref
Amir Aref
TCTravis J. Cohoon
Travis J. Cohoon
TBThanh U. Barbie
Thanh U. Barbie
YIYu Imamura
Yu Imamura
DBDavid A Barbie
David A Barbie
Although the roles of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signaling in KRAS-driven tumorigenesis are well established, KRAS activates additional pathways required for tumor maintenance, the inhibition of which are likely to be necessary for effective KRAS-directed therapy. Here, we show that the IκB kinase (IKK)–related kinases Tank-binding kinase-1 (TBK1) and IKKϵ promote KRAS-driven tumorigenesis by regulating autocrine CCL5 and interleukin (IL)-6 and identify CYT387 as a potent JAK/TBK1/IKKϵ inhibitor. CYT387 treatment ablates RAS-associated cytokine signaling and impairs Kras-driven murine lung cancer growth. Combined CYT387 treatment and MAPK pathway inhibition induces regression of aggressive murine lung adenocarcinomas driven by Kras mutation and p53 loss. These observations reveal that TBK1/IKKϵ promote tumor survival by activating CCL5 and IL-6 and identify concurrent inhibition of TBK1/IKKϵ, Janus-activated kinase (JAK), and MEK signaling as an effective approach to inhibit the actions of oncogenic KRAS.Significance: In addition to activating MAPK and PI3K, oncogenic KRAS engages cytokine signaling to promote tumorigenesis. CYT387, originally described as a selective JAK inhibitor, is also a potent TBK/IKKϵ inhibitor that uniquely disrupts a cytokine circuit involving CCL5, IL-6, and STAT3. The efficacy of CYT387-based treatment in murine Kras-driven lung cancer models uncovers a novel therapeutic approach for these refractory tumors with immediate translational implications. Cancer Discov; 4(4); 452–65. ©2014 AACR.This article is highlighted in the In This Issue feature, p. 377